DES PLAINES, Ill., June 28 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT [1]) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nations most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.. Abbott received independent 510(k) clearances for both the Abbott RealTime Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) assay and the Abbott m2000 System. They are required to be used together as a system for the detection of CT/NG from multiple specimen types including urine, urethral, vaginal and endocervical swabs. Also cleared was the Abbott multi-Collect Specimen Collection Kit, a unique device for collection and room-temperature transportation of multiple samples, including urine samples and endocervical, vaginal and male urethral swab specimens, in ...
Trovagene, Inc. has announced successful development of its first molecular diagnostic test capable of detecting KRAS mutations from a urine specimen. Transfer of the transrenal KRAS test to the companys CLIA lab is expected to be completed in December 2012 with commercial availability expected in January 2013.
Methods and compositions are provided for the identification of a molecular diagnostic test for lung cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classif
QuickFISH™ is a new molecular diagnostic technology, from AdvanDx, that significantly advances time-to-result and ease-of-use. Providing species identification of bacteria directly from positive blood cultures in just 20 minutes, it will help clinicians, consultant microbiologists and hospital pharmacists greatly improve antibiotic therapy for patients with dangerous bacterial pathogen infections. Earlier identification of the cause of bloodstream infections will ensure better patient ou
Tuberculosis (TB) is an infectious disease that remains an important public health problem at the global level. It is one of the main causes of morbidity and mortality, due to the emergence of antibiotic resistant Mycobacterium strains and HIV co-infection. Over the past decade, important progress has been made for better control of the disease. While microscopy and culture continue to be indispensible for laboratory diagnosis of tuberculosis, the range of several molecular diagnostic tests, including the nucleic acid amplification test (NAAT) and whole-genome sequencing (WGS), have expanded tremendously. They are becoming more accessible not only for detection and identification of Mycobacterium tuberculosis complex in clinical specimens, but now extend to diagnosing multi-drug resistant strains. Molecular diagnostic tests provide timely results useful for high-quality patient care, low contamination risk, and ease of performance and speed. This review focuses on the current diagnostic tests in use,
Cambridge, UK, 15th April 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has partnered with The Foundation for Innovative New Diagnostics (FIND) to develop a rapid, high-throughput malaria diagnostic assay for screening patients in the developing world.. The partnership will allow FIND to access Lumoras technologies such as BART (Bioluminescent Assay in Real Time) and the companys expertise to develop a novel test that will allow rapid screening on a large scale.. Strategies for the elimination of malaria are held back by lack of screening technologies for use in the field that can detect hidden or low parasitemia malaria infections, and thus stamp out the final cases. Such screening would also then help to keep these populations malaria free. The first field test with sufficient sensitivity to detect as few as one malaria parasite in a finger-prick blood sample has recently been developed and released by FIND and Eiken ...
The Xpert MTB/RIF is a cartridge based nucleic acid amplification test, automated diagnostic test that can identify Mycobacterium tuberculosis (MTB) DNA and resistance to rifampicin (RIF) by nucleic acid amplification test (NAAT). It was co-developed by the laboratory of Professor David Alland at the University of Medicine and Dentistry of New Jersey (UMDNJ). Cepheid Inc. and Foundation for Innovative New Diagnostics, with additional financial support from the US National Institutes of Health (NIH). In December 2010, the World Health Organization (WHO) endorsed the Xpert MTB/RIF for use in TB endemic countries. This followed 18 months of assessment of its field effectiveness in TB, MDR-TB and TB/HIV co-infection. This test, and others that are likely to follow, could have the potential to improve the diagnosis of TB in those that are likely to be missed by traditional tests. Tuberculosis is one of the deadliest public health threats today. Traditionally, tuberculosis is mostly being diagnosed by ...
The APTIMA HPV Assay is an in vitro nucleic acid amplification test for the qualitative detection of E6/E7 viral messenger RNA (mRNA) from 14 high-risk types of human papillomavirus (HPV) in cervical specimens. The high-risk HPV types detected by the assay include: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The APTIMA HPV Assay does not discriminate between the 14 high-risk types. Cervical specimens collected in ThinPrep Pap Test vials containing PreservCyt® Solution with commercially available collection devices (broom-type device or cytobrush/spatula combination) may be tested with the APTIMA HPV Assay either pre- or post-Pap processing. The assay is used with the TIGRIS System and the PANTHER System.. The objective is to establish that APTIMA HPV Assay performance on the PANTHER System is comparable to performance on the TIGRIS System. ...
According to MarketIntelReports Global Molecular Diagnostic Market by Manufacturers, Regions, Type and Application, Forecast to 2021:. Browse 103 Pages and an in-depth TOC on Molecular Diagnostic Market here. http://www.marketintelreports.com/report/gir0028/global-molecular-diagnostic-market-by-manufacturers-regions-type-and-application-forecast-to-2021. Molecular Diagnostics can be described as the method of analyzing the biological markers in the genome and proteome in order to identify the gene expression by applying molecular biology. It is helpful in diagnosing the diseases and risks involved. Molecular diagnostic testing also helps to decide the therapies that are suitable for individual patients. New technologies have qualified the instruments in providing the correct results. This ability in the tool resulted in the increased acceptance of molecular diagnostics. The concept of personalized medicine has also evolved from the Molecular Diagnostic Market. Clinical applications of this ...
According to MarketIntelReports Global Molecular Diagnostic Market by Manufacturers, Regions, Type and Application, Forecast to 2021:. Browse 103 Pages and an in-depth TOC on Molecular Diagnostic Market here. http://www.marketintelreports.com/report/gir0028/global-molecular-diagnostic-market-by-manufacturers-regions-type-and-application-forecast-to-2021. Molecular Diagnostics can be described as the method of analyzing the biological markers in the genome and proteome in order to identify the gene expression by applying molecular biology. It is helpful in diagnosing the diseases and risks involved. Molecular diagnostic testing also helps to decide the therapies that are suitable for individual patients. New technologies have qualified the instruments in providing the correct results. This ability in the tool resulted in the increased acceptance of molecular diagnostics. The concept of personalized medicine has also evolved from the Molecular Diagnostic Market. Clinical applications of this ...
The Geneva-based not-for-profit foundation FIND and Japanese diagnostics company Eiken announced today that a next-generation molecular test designed specifically for sleeping sickness -- a deadly parasitic disease also known as human African trypanosomiasis -- is ready to enter accelerated field trials in sites across the Democratic Republic of Congo and Uganda.
... DES PLAINES Ill. span class xn-ch...,Abbott,to,Collaborate,With,GSK,on,Molecular,Diagnostic,Test,to,Select,Candidate,Patients,for,Future,Skin,Cancer,Immunotherapy,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Background Only between 25 to 35% of stage II and IIIA colon cancer patients will experience a relapse of their disease and may benefit from adjuvant chemotherapy. ColoPrint is a gene expression classifier that can predict disease relapse in patients with early-stage colorectal cancer and helps to identify patients with higher risk of relapse.. Methods ColoPrint was developed using whole genome expression data and was validated in public datasets and an independent patient cohort of 206 patients (Salazar et al., JCO 2011). The signature was translated to a customized 8-pack microarray. Positive and negative hybridization control genes monitor the quality of hybridization and a colon specific normalization gene set (n = 461) guarantee reliability of results. Reproducibility and precision studies with 20 times 6 samples were performed by multiple operators on multiple days. Additional independent patient cohorts were validated on the customized arrays. Uni- and multi-variate analyses were ...
...- THEROS CancerTYPE ID(R) predicts cancer origin with 75 percent accur... ...SAN DIEGO June 1 /- bioTheranostics a bioMerieux compan... ...,Data,From,Clinical,Study,of,bioTheranostics,Molecular,Diagnostic,Test,Presented,at,American,Society,of,Clinical,Oncology,Annual,Meeting,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Rationale The clinical impact of Xpert MTB/RIF for tuberculosis (TB) diagnosis in high HIV-prevalence settings is unknown. Objective To determine the diagnostic accuracy and impact of Xpert MTB/RIF among high-risk TB suspects. Methods We prospectively enrolled consecutive, hospitalized, Ugandan TB suspects in two phases: baseline phase in which Xpert MTB/RIF results were not reported to clinicians and an implementation phase in which results were reported. We determined the diagnostic accuracy of Xpert MTB/RIF in reference to culture (solid and liquid) and compared patient outcomes by study phase. Results 477 patients were included (baseline phase 287, implementation phase 190). Xpert MTB/RIF had high sensitivity (187/237, 79%, 95% CI: 73-84%) and specificity (190/199, 96%, 95% CI: 92-98%) for culture-positive TB overall, but sensitivity was lower (34/81, 42%, 95% CI: 31-54%) among smear-negative TB cases. Xpert MTB/RIF reduced median days-to-TB detection for all TB cases (1 [IQR 0-26] vs. 0 [IQR
We conducted an external quality assessment of Zika virus molecular diagnostic tests in Brazil using a new Zika virus standard. Of 15 laboratories, 73% showed limited sensitivity and specificity. Viral load estimates varied significantly. Continuous quality assurance is required for adequate estimates of Zika virus-associated disease and determination of patient care.
Factors Influencing Growth of the Molecular Diagnostic Reagent Market. The global molecular diagnostic reagent market is expected to be driven by the positive research and development present. The National Institute of biologics designed for in-vitro diagnostics for HIV virus, hepatitis virus issues great interest in clear molecular diagnostic reagents for better test results.. Molecular diagnostic laboratories are also responsible in providing end user opinion to the supply side of molecular diagnostic reagents products. Such call make up a well-integrated plan for complete response effect, which the manufacturer later can work in order to increase their market value and product reach.. Clinically, the market value for molecular diagnostic reagents is generally dependent on disease prevalence, as molecular diagnosis is clinically the first line of treatment. Increase in patient count directly affects the market expansion of parallel molecular diagnostic reagents. Get To Know Methodology of ...
Use PCR technology to facilitate HLA-B*5701 screening and better manage HIV patients who could potentially have hypersensitivity reactions to abacavir
Business Description. Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleic acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individuals risk for developing disease later in life (predictive medicine), identify a patients likelihood of responding to drug therapy and guide a patients dosing to ensure optimal treatment (personalized medicine), or assess a patients risk of disease progression and disease recurrence (prognostic medicine).. Company offers 13 commercial molecular diagnostic ...
Serum HCV RNA values were measured during the clinical trials using the Roche COBAS AmpliPrep/COBAS Taqman HCV test (version 2.0) with a lower limit of quantification (LLOQ) of 15 IU/mL (except for SURVEYOR-1 and SURVEYOR-2 which used the Roche COBAS TaqMan real-time reverse transcriptase-PCR (RT-PCR) assay v. 2.0 with an LLOQ of 25 IU/mL). The primary endpoint across all clinical trials was sustained virologic response (SVR12), defined as HCV RNA less than LLOQ at 12 weeks after the end of treatment. Relapse was defined as HCV RNA ≥ LLOQ after end-of-treatment response among subjects who completed treatment. Subjects with missing HCV RNA data, such as those who discontinued due to an adverse event, subject withdrawal or were lost to follow-up, were counted as SVR12 failures ...
Sales Forecasts by Market Segment. AFP Testing: Market Shares of Major Suppliers. CEA Testing: Market Shares of Major Suppliers. PSA Testing: Market Shares of Major Suppliers. Molecular Diagnostic Market. Molecular Diagnostics Test Volume Forecasts by Application. Molecular Diagnostic Sales Forecasts by Application. Market Shares of Major Supplier of Molecular Diagnostic Tests Market Shares of Major Supplier of HIV/Hepatitis Blood Screening Assays Hematology and Flow Cytometry Markets. Hematology and Flow Cytometry Test Volume Forecasts Hematology and Flow Cytometry Diagnostics Market Forecasts. Hematology Diagnostics Market Forecasts by Market Segment. Market Shares of Major Suppliers of Hematology Instruments and Consumables. Flow Cytometry Diagnostics Market Forecasts by Market Segment. Market Shares of Major Suppliers of Flow Cytometry Instruments and Consumables. Coagulation Testing Market. Coagulation Test Volume Forecasts by Market Segment. Coagulation Reagent Sales Forecasts by Market ...
The Verigene(®)Clostridium difficile nucleic acid test (Verigene(®) CDF test) is an automatic and rapid detection system for the genes encoding tcdA, tcdB, binary toxin, and the single nucleotide deletion at base pair 117 in the tcdC based on microarray and PCR amplification. We compared the performance of the Verigene(®) CDF test to that of two enzyme immunoassays, C. DIFF QUIK CHEK COMPLETE and X/Pect Toxin A/B, using 118 specimens. We found overall concordance rates of 81.4% and 78.8% between C. DIFF QUIK CHEK COMPLETE and Verigene(®) CDF test, and X/Pect Toxin A/B and Verigene(®) CDF test ...
TY - JOUR. T1 - Comparison of Abbott RealTime genotype II, GeneMatrix restriction fragment mass polymorphism and Sysmex HISCL HCV Gr assays for hepatitis C virus genotyping. AU - Han, Mi Soon. AU - Park, Yongjung. AU - Kim, Hyonsuk. PY - 2017/7/1. Y1 - 2017/7/1. N2 - Hepatitis C virus (HCV) genotype is a predictive marker for treatment response. We sequentially evaluated the performances of two nucleic acid amplification tests (NAATs) and one serology assay for HCV genotype: Abbott RealTime genotype II (RealTime II), GeneMatrix restriction fragment mass polymorphism (RFMP), and Sysmex HISCL HCV Gr (HISCL Gr). We examined 281 clinical samples with three assays. The accuracy was assessed using the HCV Genotype Performance Panel PHW204 (SeraCare Life Sciences) for two NAATs. Discrepant cases were re-genotyped by the Versant HCV v.2.0 (line probe 2.0) assay. With the RealTime II assay, clinic samples were analyzed as follows: genotypes 1b (43.1%), 2 (40.2%), 1 subtypes other than 1a and 1b (12.5%), ...
Globally there still remains a large gap (64%) between the incidence and number of new TB cases diagnosed. Only 2 million of the 6.6 million (30%) notified cases were tested for RIF resistance, 24% for new and 70% for previously treated TB patients.1. Culture-confirmed TB has been reported in England at 61.8% in 2017, which has slightly decreased from 64% in 2016 but similar to previous years. Sixty-three per cent of pulmonary TB patients had sputum smear results reported and 56% were positive.2 With the goals of the World Health Organization (WHO) End TB Strategy which aims to achieve a 90% reduction in TB deaths and 80% reduction in TB incidence by 2030,1 there has been much focus on the development of diagnostic tests, including point of care tests.. For MDR-TB, rapid molecular diagnostic tests such as the Xpert MTB/RIF, a cartridge-based automated molecular assay which was endorsed by WHO in 2016 as an initial test for TB and detection of RIF resistance, has significantly increased case ...
DWBio.com Science Blog | Whats in a test? Or better yet whats in 55 SARS-CoV-2 / COVID-19 molecular diagnostic tests? Plenty. 55 FDA EUAs indicate that nine different test formats are used, ranging from RT-PCR, to digital PCR, to isothermal amplification, to LAMP with a CRISPR enzyme. | COVID-19, Shoreline Community College
Cepheids innovative oncology program offers a growing menu of molecular diagnostic tests that currently focus on cancers of the breast, bladder, and blood.
Luminex Corporation (LMNX), a developer of biological testing technologies, has forged a definitive agreement to buy Madison, Wisconsin-based privately-held diagnostic testing company EraGen Biosciences, Inc. for $34 million in cash.. The transaction, which is subject to the clearance of EraGen shareholders and other customary conditions, is expected to complete within the next few weeks.. EraGen, with annual sales of $8 million, makes molecular reagent products for infectious diseases and genetic-based conditions. The companys products are based on its proprietary MultiCode technology platform.. EraGen received, in May 2010, the approval of the U.S. Food and Drug Administration (FDA) for its MultiCode-RTx HSV 1&2 Kit. It is the first FDA-approved molecular test for the herpes simplex virus (HSV).. The acquisition will provide Luminex a highly complementary portfolio of molecular diagnostic tests based on the MultiCode platform. Besides expanding its product offering to the existing ...
Identifying cancer at its earliest stage makes it treatable. Different types of cancer diagnostic tests are being used to detect various types of cancer. Among all these tests, Biopsy is the most preferred cancer diagnostic test. Biopsy, being the largest segment, is anticipated to grow at CAGR of 7.4%, indicates the report by Future Market Insights (FMI). Among all the biopsy tests, tissue biopsies and solid tumour biopsies are the preferred test to obtain an accurate diagnosis. At the same time, being non-invasive in nature, liquid biopsy test is gaining popularity.. Diagnostic companies to invest in high dollar molecular diagnostic tests. Major diagnostic companies use instruments in diagnostic and research laboratories by the means of rental contracts and exchanging long-term contracts, to buy the test reagents. For example, leading players such as Abbott and Roche Diagnostics, license their cancer test products to the partners who distribute products or use it to develop reagent kits for ...
Exosome Diagnostics, Inc. (Exosome Diagnostics) is a diagnostic company. The company develops biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome
This project will utilize the expertise of three cooperative institutions to provide the experimental validation of safe (not contaminated with live RVFV) diagnostic tools that could be distributed to regional Bio-Safety Level 2 (BSL-2) diagnostic laboratories for early detection. The project will also develop and provide the initial evaluation of a novel SERS based assay systems for viral diagnosis. ARS has and will develop molecular diagnostic tests for RVFV nucleic acid. ARS has and will develop immunological diagnostic assays base on BLS-2 generated diagnostic reagents. ARS will assist and coordinate the evaluation of these assays through cooperators. ...
Longhorn Vaccines and Diagnostics one-step reagent for sample collection and transport enhanced M. tuberculosis detection on the Xpert MTB/RIF assay.
The FDA has granted emergency use authorization for COVID-19-related diagnostic tests to Hologic (NSDQ:HOLX) and Laboratory Corporation of America (NYSE:LH).. Hologic described its new Panther Fusion SARS-CoV-2 assay as a molecular diagnostic test that detects SARS-CoV-2, the virus that causes COVID-19. The automated Panther high-throughput system is widely used across the U.S., can provide results in less than three hours and process up to 1,150 coronavirus tests in a 24-hour period, according to the Marlborough, Mass.-based company.. Hologic also said it expects to provide its laboratory customers with tens of thousands of SARS-CoV-2 tests this month as it ramps up production capacity. Starting in April, Hologic expects to produce nearly 600,000 SARS-CoV-2 tests per month, representing a 12-fold increase in the companys prior manufacturing capacity for similar tests that run on the Panther Fusion system.. Panther Fusion can also simultaneously test for other common respiratory viruses, and ...
SALT LAKE CITY-ARUP Laboratories today announced that it is making a second COVID-19 IgG antibody test available nationwide. The test, manufactured by EUROIMMUN, a PerkinElmer company, adds to ARUPs suite of COVID-19 tests offered nationwide, which includes an antibody test manufactured by Abbott and a molecular diagnostic test to detect active SARS-CoV-2 infection. ARUPs menu of more than 3,000 tests also offers cytokine tests and other assays that providers are using to help guide COVID-19 treatment decisions.
Ibis Biosciences (Abbott) has been awarded US Patent No. 9,416,409, Capture primers and capture sequence linked solid supports or molecular diagnostic tests.
Molecular Care has been established with the objective to extend the expertise and facilities of the university faculty in Molecular Biochemistry Lab. of the Department of Biochemistry for researchers, students and the community. The department is pioneer in the Punjab offering independent postgraduate degrees in Biochemistry since 1973. Molecular Biochemistry lab of the department has attained sufficiently high level of expertise and facilities that could be translated in service of the community. The establishment of Molecular Care is an excellent facility and one of its kind in Faisalabad, offering molecular diagnostic tests for humans and animals, and Research Solutions in the area of Molecular Biology to cater the needs of students and researchers of newly emerging universities and institutions. Bioinformatics is also becoming integral part of biological and molecular research. The Molecular Care is offering bioinformatics analysis both at introductory and advanced level. Training modules ...
NewGenes next generation sequencing and genotyping technologies are used to support both clinical molecular diagnostic and research services
Gen-Probe recently announced that the FDA has approved its APTIMA HPV assay, an amplified nucleic acid test that detects high-risk strains of human papillomavirus (HPV) that are associated with cervical cancer and precancerous lesions. The test has been approved to run on Gen-Probes fully automated, high-throughput TIGRIS instrument system.. The APTIMA HPV assay detects 14 high-risk HPV types associated with cervical cancer and precancerous lesions. Testing is performed from ThinPrep liquid cytology specimens routinely used for Pap testing. Unlike other FDA-approved, DNA-based HPV tests, the APTIMA HPV assay detects messenger RNA overexpressed from two viral oncogenes that are integral to the development of cervical cancer.. Most HPV infections clear up on their own, so its important to identify those persistent, high-risk infections that are most likely to lead to cervical cancer, said Tom Wright, MD, Professor of Pathology and Cell Biology at the Columbia University Medical Center. In ...
U.S. Molecular Diagnostic Analyzers and Reagents Market 2021: Supplier Shares by Test, Competitive Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review - This report presents a comprehensive analysis of the US molecular diagnostics market.
DaAn Gene is a high technology enterprise oriented in molecular diagnostic techniques. Since its establishing day in 1993, DaAn Gene has dedicated to the Molecular Diagnostics leader and consistently committed to R&D, production and service of Molecular Diagnostics. DaAn Gene has more than 20 years molecular diagnostic experience with multi-product lines like: 1. Real-time qPCR diagnostic kits and equipments 2. Automatic nucleic acid extraction 3. Pathology product 4. Immunoassay diagnostic kits. ...
Visit Aurora Diagnostics for quality molecular diagnostic testing of womens health conditions. Call us at 866-420-5512 for complete reports, and other services
Intense Research has been recently published a fresh research report Global Molecular Diagnostic Market by Manufacturers, Regions, Type and Application, F
This new report from VPGMarketResearch.com examines current and emerging assays; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic ...
Europe Molecular Diagnostic Analyzers and Reagents, 2019-2023: A 31-Country Analysis--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing This ...
2020 Germany Molecular Diagnostic Analyzers and Reagent Forecasts for 100 Tests: Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing - Supplier Shares, Volume and - Market research report and industry analysis - 13116689
U.K. Molecular Diagnostic Analyzers and Reagents Market 2021: Supplier Shares by Test, Competitive Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review U.K. - Market research report and industry analysis - 10930469
Learn more about Molecular Diagnostic Case Study. We enable science by offering product choice, services, process excellence and our people make it happen.
In total, 109 of 238 (45.8%) specimens were culture-positive for M. tuberculosis complex (MTBC), and of these, 67 isolates were rifampicin resistant (RIF-R) by phenotypic DST, and 64/67 (95.5%) were isoniazid resistant (INH-R). Compared to culture of the same specimen, a single direct Xpert was more sensitive for detecting MTBC (95.3%, 95% confidence interval [CI], 90.0-98.3%) than direct (59.6%, 95% CI, 50.2-68.5%) or concentrated smear (85.3%, 95% CI, 77.7-91.1%) or LJ culture (80.8%, 95% CI, 72.4-87.5%); specificity was 86.0% (95% CI 78.9-91.3%). Compared with MGIT DST, Xpert correctly identified 98.2% (95% CI, 91.5-99.9%) of RIF-R and 95.5% (95% CI, 85.8-99.2%) of RIF-susceptible (RIF-S) specimens. In a subset of 104 specimens, the sensitivity of TB-Biochip for MTBC detection compared to culture was 97.3% (95% CI, 91.0-99.5%); specificity was 78.1% (95% CI, 61.5- 89.9%). TB-Biochip correctly identified 100% (95% CI, 94.2-100%) of RIF-R, 94.7% (95% CI, 76.7-99.7%) of RIF-S, 98.2% (95% CI, ...
Background. Genetic testing has evolved from a niche speciality for diagnosis of rare disorders and carrier screening to subtyping of complex medical conditions for targeted treatment. Genes causing monogenic disorders are well characterised, but risk management of multifactorial and polygenic disorders guided from the genetic background remains a challenge. Objective. This study describes the use of a pathology-supported genetic testing (PSGT) strategy designed to facilitate the move from single- to multi-gene testing and next-generation sequencing (NGS). Methods. In contrast to direct-to-consumer genetic testing, PSGT requires preselection of patients and data integration to determine current and future risk implications. To enable this process, a genomics database resource generated at the interface between the laboratory and clinic is available for clinical interpretation. Results. The PSGT approach led to the development of testing algorithms for improved clinical management of patients with cancer
This product is a simple detection kit by plate assay for senescence-associated β-galactosidase (SA-β-gal) activity which is used as a marker for senescent cells. By simply adding SPiDER-βGal, a reagent for detection of β-galactosidase, to 96 well plates, this kit allows you to quantify SA-β-gal activity and makes it possible to evaluate multiple specimens. When normalization is done by the results obtained by counting cells, quantifying nucleic acids (the relevant product), or quantifying proteins, the measured values obtained using this kit become available for evaluating SA-β-gal activity according to cell number.. ...
KÉKES Ede, SZEGEDI János, VÁLYI Péter. [The course and outcome of an pandemic caused by coronaviruses are determined by many factors, such as the strength and dose of the infectious virus, the immune system of the affected individual, the underlying diseases, the speed of virus spread, age and environmental factors and methods of control. In old age, there is a significantly higher risk of developing severe cases and fatalities. The rate of loss of life is particularly high in social care and nursing homes. Hypertension as the underlying disease is the most common cause of death, but hypertension alone is not an independence risk factor, but the main reason is the co-morbidities and complications associated with viral infection. In the epidemic situation, the treatment and care of hypertensive patients poses special challenges for health and active primary and specialist care workers and, of course, for hypertonologists. The Hungarian Society of Hypertension expressed its opinions and ...